Lynk Pharmaceuticals
PrivateLast Round
Series C
Extension
Sep 21, 2023
Est. Valuation
$467.6M
Total Funding Raised
$154.95M
Company Overview
Lynk Pharmaceuticals is a clinical-stage biotechnology company that develops innovative small molecule drugs to treat tumors, autoimmune diseases, and inflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lynk Pharmaceuticals Comparables
Compare Lynk Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Reistone Biopharma | 87% | |
| 杭州高光制药股份有限公司 | 87% | |
| Alumis | 84% |
Lynk Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 21, 2023 | ||||
| Series C | May 31, 2023 | ||||
| Series B | Aug 27, 2021 | ||||
| Series A Extension | Dec 1, 2020 | ||||
| Series A Extension | Dec 1, 2020 | ||||
Series A | Jan 1, 2020 |
Key People
Founding team and executive leadership
Lynk Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series C Extension, Series B |
| Kaitai Capital | Angel, Seed, Series A |
| 健壹资本 | Angel, Seed |
| Tailong Investment | Series C |
| Legend Capital | Series B, Series A Extension |
| Howbuy Primary Fund | Series C Extension |
| Liando Investment | Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2025
Preparing for NDA submission and international audits.
- Sep 21, 2023
$17M round led by China Grand Prosperity Investment.
Lynk Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Lynk Pharmaceuticals's valuation, stock price, and market status.
Is Lynk Pharmaceuticals a public or private company?
Lynk Pharmaceuticals is a private company.
What is the current stock price of Lynk Pharmaceuticals?
Lynk Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Lynk Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lynk Pharmaceuticals worth (valuation)?
Lynk Pharmaceuticals's valuation is estimated at $467.6M based on funding round data.
Can I buy Lynk Pharmaceuticals stock?
Lynk Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lynk Pharmaceuticals's last funding round?
Lynk Pharmaceuticals's most recent funding round was Series C Extension on September 21, 2023.
Who are the main investors in Lynk Pharmaceuticals?
Key investors in Lynk Pharmaceuticals include Legend Capital, China Grand Prosperity Investment (CGP), Lilly Asia Ventures, Decheng Capital.
Will Lynk Pharmaceuticals IPO soon?
No public IPO plans have been announced for Lynk Pharmaceuticals.
How can I track Lynk Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Lynk Pharmaceuticals's shares on secondary markets.